. ALT and/or AST ≤ 3 x ULN, and bilirubin and ALP ≤ 2 x ULN.
Exclusion criteria
8. Ability to understand and the willingness to sign a written informed consent document.
9. Agree to sign consent to the long-term follow-up protocol PA17-0843 to fulfill the institutional responsibilities to various regulatory agencies.
. Lymphoma in CR with no measurable sites of disease.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is specifically for people whose lymphoma either didn't respond to initial treatment or came back early — does my situation actually fit that description, and is this worth pursuing given where I am in my treatment journey?
2Since this is a Phase 2 trial testing CD70-targeted CAR NK cells, what is known so far about the safety of this type of cell therapy from earlier research, and what kinds of side effects should I realistically prepare for?
3The trial isn't recruiting yet — how long might it be before it opens, and given how quickly diffuse large B-cell lymphoma or Hodgkin lymphoma can progress, is waiting for this trial a realistic option for me?
4Because the primary thing being measured here is safety and adverse events rather than whether the treatment works, what does that mean for how much we actually know about whether CD70 CAR NK cells are effective at this stage?
5Are there standard salvage treatments or other clinical trials already open that I should consider alongside or instead of this one, especially since this trial hasn't started enrolling yet?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Safety and Adverse Events (AEs)
Timeframe: Through study completion; an average of 1 year